Is Entero Therapeutics, Inc. (ENTO) a Buy, Sell, or Hold?
NASDAQ : ENTO
Entero Therapeutics, Inc.
$2.85 USD
-$0.15 (-5.0%)
- Volume
- 93.18K
- Average Volume
- 216.27K
- Market Capitalization
- $13.58M
- P/E Ratio
- -0.71
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $5.84
- Year Low
- $0.97
- Day High
- —
- Day Low
- —
- Payout Ratio
- -$0.04
- Current Ratio
- $0.16
Company Overview
NASDAQ
Jason David Sawyer
Biotechnology
Healthcare
ENTO
2
US
USD
Liquidity Metrics
0.12
0.16
0.16
0.02
-0.04
Sales & Valuation
$36251
151.26
0.66
-1.69
-1.50
Profitability
-$4.16
-$6.55M
-11664.78%
-12662.33%
-18.69%
-18.11%
P/E Metrics
-0.71
-0.05
-0.05
Analyst Price Target & Rating
0/5
1 Analysts
%
Financial Health Scores
-6.24
3/9
-$13.65M
$47.97M
$20.47M
-$1.58M
Key Metrics (TTM)
$12.8M
171.86
-1.54
0.16
-18.69%
-26.65%
-61.94%
-62.99%
8436 days
Company Executives
| Name | Title |
|---|---|
| Jason David Sawyer | Chief Executive Officer & Director |
| Anna Skowron | Interim Chief Financial Officer |
Poll Results
No votes yet today — be the first to share your view!
About Entero Therapeutics, Inc. (NASDAQ:ENTO) Stock
Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company formerly known as First Wave BioPharma, Inc. (and prior to September 2021, AzurRx BioPharma, Inc.), is dedicated to discovering and advancing localized, non-systemic treatments for various gastrointestinal conditions. Its development pipeline features several key therapeutic candidates: latiglutenase, an oral biotherapeutic formulated to break down gluten into non-immunogenic peptides for celiac disease patients; adrulipase, a recombinant lipase enzyme engineered to facilitate the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist aimed at addressing gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for individuals with inflammatory bowel di ... seases such as ulcerative colitis and Crohn's disease. Furthermore, the company is developing CypCel, a management tool designed to monitor the intestinal health of recovering celiac disease patients. Founded in 2014, the company's operations are based in Boca Raton, Florida.
Frequently Asked Questions
-
What is the current Entero Therapeutics, Inc. (ENTO) stock price?
-
Entero Therapeutics, Inc.(NASDAQ:ENTO) stock price is $2.85 in the last trading session. During the trading session, ENTO stock reached the peak price of $5.84 while $0.969 was the lowest point it dropped to. The percentage change in ENTO stock occurred in the recent session was --5.0% while the dollar amount for the price change in ENTO stock was -$0.15.
-
ENTO's industry and sector of operation?
-
The NASDAQ listed ENTO is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ENTO?
-
Jason David Sawyer | Chief Executive Officer & Director
Anna Skowron | Interim Chief Financial Officer
|
|
| -
How many employees does ENTO have?
-
Number of ENTO employees currently stands at 2. ENTO operates from 777 Yamato Road, Boca Raton, FL 33431, US.
-
Link for ENTO official website?
-
Official Website of ENTO is: https://enterothera.com
-
How do I contact ENTO?
-
ENTO could be contacted at phone #(561) 589-7020 and can also be accessed through its website. ENTO operates from 777 Yamato Road, Boca Raton, FL 33431, US.
-
How many shares of ENTO are traded daily?
-
The average number of ENTO shares traded daily for last 3 months was 216.27K.
-
What is the market cap of ENTO currently?
-
The market value of ENTO currently stands at $13.58M with its latest stock price at $2.85